Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| ABBOTT LABORATORIESABT · Entity 2314 | EXECUTIVE VICE PRESIDENT | August 11, 2026 | August 13, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
ABBOTT LABORATORIES
Report date August 11, 2026 · Filed August 13, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common shares without par valueSEC Table I · non-derivative | Direct | 70,724 |
Reported balance
After 2026-08-11 transaction · row 1
1 source rowRow 1 · 2026-08-11 · Sale · Disposed 5,850 · Balance 70,724 |
| Common shares without par valueSEC Table I · non-derivative | IndirectProfit Sharing Trust | 0 |
Reported balance
After 2026-08-12 transaction · row 2
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 2 · 2026-08-12 · Other · Disposed 12 · Balance 0 |
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| August 12, 2026 Filed Aug 13, 2026 21:14 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | OtherCommon shares without par value | 12 | $107.99 | $1,295.88 |
DisclosureSEC source: 0001867666-26-000013 · form4-08132026_090844.xml · nonDerivative · entry 2 Morrone Louis H. · CIK 0001867666 · EXECUTIVE VICE PRESIDENT 10b5-1 filing: No plan indicated Ownership: Indirect · Profit Sharing Trust Disclosed balance after: 0 Read SEC document |
| August 11, 2026 Filed Aug 13, 2026 21:14 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | SaleCommon shares without par value | 5,850 | $109.83 | $642,505.50 |
DisclosureSEC source: 0001867666-26-000013 · form4-08132026_090844.xml · nonDerivative · entry 1 Morrone Louis H. · CIK 0001867666 · EXECUTIVE VICE PRESIDENT 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 70,724 Read SEC document |
| June 30, 2026 Filed Jul 1, 2026 21:04 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | Tax withholdingCommon shares without par value | 269 | $92.71 | $24,938.99 |
DisclosureSEC source: 0001867666-26-000009 · form4-07012026_090726.xml · nonDerivative · entry 1 Morrone Louis H. · CIK 0001867666 · EXECUTIVE VICE PRESIDENT 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 76,574 Read SEC document |
| March 02, 2026 Filed Mar 4, 2026 01:06 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | SaleCommon shares without par value | 1,144 | $115.58 | $132,223.52 |
DisclosureSEC source: 0001867666-26-000007 · form4-03042026_010349.xml · nonDerivative · entry 2 Morrone Louis H. · CIK 0001867666 · EXECUTIVE VICE PRESIDENT 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 76,843 Read SEC document |
| February 27, 2026 Filed Mar 4, 2026 01:06 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | Tax withholdingCommon shares without par value | 4,040 | $116.26 | $469,690.40 |
DisclosureSEC source: 0001867666-26-000007 · form4-03042026_010349.xml · nonDerivative · entry 1 Morrone Louis H. · CIK 0001867666 · EXECUTIVE VICE PRESIDENT 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 77,987 Read SEC document |
| February 24, 2026 Filed Feb 26, 2026 23:52 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | GrantOption (right to buy) · Derivative | 63,561 | $0.00 Strike: $114.60 | $0.00 |
DisclosureSEC source: 0001867666-26-000002 · form4-02262026_110221.xml · derivative · entry 3 Morrone Louis H. · CIK 0001867666 · EXECUTIVE VICE PRESIDENT 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 63,561 Underlying: Common Shares · 63,561 shares Expires 2036-02-23 F3 · security: Employee stock option granted pursuant to the Abbott Laboratories 2017 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3. The option becomes exercisable in annual increments of 21,187 on February 24, 2027, 21,187 on February 24, 2028, and 21,187 on February 24, 2029. Read SEC document |
| February 24, 2026 Filed Feb 26, 2026 23:52 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | GrantCommon shares without par value | 15,418 | $0.00 | $0.00 |
DisclosureSEC source: 0001867666-26-000002 · form4-02262026_110221.xml · nonDerivative · entry 1 Morrone Louis H. · CIK 0001867666 · EXECUTIVE VICE PRESIDENT 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 82,027 F1 · shares: These shares represent a performance-based restricted stock award under the Abbott Laboratories 2017 Incentive Stock Program. The award has a 3-year term, with no more than 1/3 of the award vesting in any one year upon Abbott reaching a minimum return on equity target. The award includes the right to have shares withheld for tax purposes. Read SEC document |
| June 30, 2025 Filed Jul 1, 2025 20:55 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | Tax withholdingCommon shares without par value | 269 | $134.38 | $36,148.22 |
DisclosureSEC source: 0001415889-25-018725 · form4-07012025_080744.xml · nonDerivative · entry 1 Morrone Louis H. · CIK 0001867666 · EXECUTIVE VICE PRESIDENT 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 66,609 Read SEC document |
| March 03, 2025 Filed Mar 5, 2025 00:49 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | SaleCommon shares without par value | 1,111 | $138.17 | $153,506.87 |
DisclosureSEC source: 0001415889-25-006788 · form4-03052025_120335.xml · nonDerivative · entry 2 Morrone Louis H. · CIK 0001867666 · EXECUTIVE VICE PRESIDENT 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 66,878 Read SEC document |
| February 28, 2025 Filed Mar 5, 2025 00:49 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | Tax withholdingCommon shares without par value | 4,386 | $135.87 | $595,925.82 |
DisclosureSEC source: 0001415889-25-006788 · form4-03052025_120335.xml · nonDerivative · entry 1 Morrone Louis H. · CIK 0001867666 · EXECUTIVE VICE PRESIDENT 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 67,989 Read SEC document |
| February 25, 2025 Filed Feb 27, 2025 23:35 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | GrantOption (right to buy) · Derivative | 38,108 | $0.00 Strike: $135.42 | $0.00 |
DisclosureSEC source: 0001415889-25-005900 · form4-02272025_110234.xml · derivative · entry 3 Morrone Louis H. · CIK 0001867666 · EXECUTIVE VICE PRESIDENT 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 38,108 Underlying: Common Shares · 38,108 shares Expires 2035-02-24 F3 · security: Employee stock option granted pursuant to the Abbott Laboratories 2017 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3. The option becomes exercisable in annual increments of 12,702 on February 25, 2026, 12,703 on February 25, 2027, and 12,703 on February 25, 2028. Read SEC document |
| February 25, 2025 Filed Feb 27, 2025 23:35 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | GrantCommon shares without par value | 10,232 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-25-005900 · form4-02272025_110234.xml · nonDerivative · entry 1 Morrone Louis H. · CIK 0001867666 · EXECUTIVE VICE PRESIDENT 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 72,375 F1 · shares: These shares represent a performance-based restricted stock award under the Abbott Laboratories 2017 Incentive Stock Program. The award has a 3-year term, with no more than 1/3 of the award vesting in any one year upon Abbott reaching a minimum return on equity target. The award includes the right to have shares withheld for tax purposes. Read SEC document |
| January 28, 2025 Filed Jan 31, 2025 00:33 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | SaleCommon shares without par value | 2,644 | $127.39 | $336,819.16 |
DisclosureSEC source: 0001415889-25-002423 · form4-01312025_120112.xml · nonDerivative · entry 1 Morrone Louis H. · CIK 0001867666 · EXECUTIVE VICE PRESIDENT 10b5-1 filing: No plan indicated Ownership: Indirect · Profit Sharing Trust Disclosed balance after: 0 F1 · shares: Includes shares acquired pursuant to a dividend reinvestment feature. F2 · balance_after: Balance in the Abbott Laboratories Stock Retirement Trust as of January 29, 2025. Read SEC document |
| July 01, 2024 Filed Jul 2, 2024 20:39 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | Tax withholdingCommon shares without par value | 556 | $103.91 | $57,773.96 |
DisclosureSEC source: 0001415889-24-018920 · form4-07022024_080752.xml · nonDerivative · entry 2 Morrone Louis H. · CIK 0001867666 · EXECUTIVE VICE PRESIDENT 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 62,143 Read SEC document |
| June 30, 2024 Filed Jul 2, 2024 20:39 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | Tax withholdingCommon shares without par value | 269 | $103.91 | $27,951.79 |
DisclosureSEC source: 0001415889-24-018920 · form4-07022024_080752.xml · nonDerivative · entry 1 Morrone Louis H. · CIK 0001867666 · EXECUTIVE VICE PRESIDENT 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 62,699 Read SEC document |
| March 01, 2024 Filed Mar 5, 2024 00:14 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | SaleCommon shares without par value | 801 | $118.50 | $94,918.50 |
DisclosureSEC source: 0001415889-24-006413 · form4-03052024_120313.xml · nonDerivative · entry 2 Morrone Louis H. · CIK 0001867666 · EXECUTIVE VICE PRESIDENT 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 62,968 Read SEC document |
| February 29, 2024 Filed Mar 5, 2024 00:14 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | Tax withholdingCommon shares without par value | 3,455 | $120.05 | $414,772.75 |
DisclosureSEC source: 0001415889-24-006413 · form4-03052024_120313.xml · nonDerivative · entry 1 Morrone Louis H. · CIK 0001867666 · EXECUTIVE VICE PRESIDENT 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 63,769 Read SEC document |
| February 21, 2024 Filed Feb 23, 2024 22:40 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | GrantOption (right to buy) · Derivative | 46,257 | $0.00 Strike: $116.98 | $0.00 |
DisclosureSEC source: 0001415889-24-005107 · form4-02232024_100240.xml · derivative · entry 3 Morrone Louis H. · CIK 0001867666 · EXECUTIVE VICE PRESIDENT 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 46,257 Underlying: Common Shares · 46,257 shares Expires 2034-02-20 F3 · security: Employee stock option granted pursuant to the Abbott Laboratories 2017 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3. The option becomes exercisable in annual increments of 15,419 on February 21, 2025, 15,419 on February 21, 2026, and 15,419 on February 21, 2027. Read SEC document |
| February 21, 2024 Filed Feb 23, 2024 22:40 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | GrantCommon shares without par value | 12,309 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-24-005107 · form4-02232024_100240.xml · nonDerivative · entry 1 Morrone Louis H. · CIK 0001867666 · EXECUTIVE VICE PRESIDENT 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 67,224 F1 · shares: These shares represent a performance-based restricted stock award under the Abbott Laboratories 2017 Incentive Stock Program. The award has a 3-year term, with no more than 1/3 of the award vesting in any one year upon Abbott reaching a minimum return on equity target. The award includes the right to have shares withheld for tax purposes. Read SEC document |
| July 01, 2023 Filed Jul 5, 2023 15:55 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | Tax withholdingCommon shares without par value | 556 | $109.02 | $60,615.12 |
DisclosureSEC source: 0001104659-23-077919 · tm2320556-2_4seq1.xml · nonDerivative · entry 2 Morrone Louis H. · CIK 0001867666 · EXECUTIVE VICE PRESIDENT 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 54,915 Read SEC document |
| June 30, 2023 Filed Jul 5, 2023 15:55 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | GrantOption (right to buy) · Derivative | 7,100 | $0.00 Strike: $108.52 | $0.00 |
DisclosureSEC source: 0001104659-23-077919 · tm2320556-2_4seq1.xml · derivative · entry 4 Morrone Louis H. · CIK 0001867666 · EXECUTIVE VICE PRESIDENT 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 7,100 Underlying: Common Shares · 7,100 shares Expires 2033-06-29 F3 · security: Employee stock option granted pursuant to the Abbott Laboratories 2017 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3. The option becomes exercisable in annual increments of 2,366 on June 30, 2024, 2,367 on June 30, 2025, and 2,367 on June 30, 2026. Read SEC document |
| June 30, 2023 Filed Jul 5, 2023 15:55 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | GrantCommon shares without par value | 1,815 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-23-077919 · tm2320556-2_4seq1.xml · nonDerivative · entry 1 Morrone Louis H. · CIK 0001867666 · EXECUTIVE VICE PRESIDENT 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 55,471 F1 · shares: These shares represent a performance-based restricted stock award under the Abbott Laboratories 2017 Incentive Stock Program. The award has a 3-year term, with no more than 1/3 of the award vesting in any one year upon Abbott reaching a minimum return on equity target. The award includes the right to have shares withheld for tax purposes. Read SEC document |
| February 28, 2023 Filed Mar 3, 2023 00:47 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | Tax withholdingCommon shares without par value | 2,534 | $99.77 | $252,817.18 |
DisclosureSEC source: 0001415889-23-003913 · form4-03032023_120307.xml · nonDerivative · entry 1 Morrone Louis H. · CIK 0001867666 · SENIOR VICE PRESIDENT 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 54,748 Read SEC document |
| February 17, 2023 Filed Feb 23, 2023 00:16 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | GrantOption (right to buy) · Derivative | 41,648 | $0.00 Strike: $106.24 | $0.00 |
DisclosureSEC source: 0001415889-23-003058 · form4-02232023_120257.xml · derivative · entry 3 Morrone Louis H. · CIK 0001867666 · SENIOR VICE PRESIDENT 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 41,648 Underlying: Common Shares · 41,648 shares Expires 2033-02-16 F3 · security: Employee stock option granted pursuant to the Abbott Laboratories 2017 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3. The option becomes exercisable in annual increments of 13,882 on February 17, 2024, 13,883 on February 17, 2025, and 13,883 on February 17, 2026. Read SEC document |
| February 17, 2023 Filed Feb 23, 2023 00:16 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | GrantCommon shares without par value | 10,560 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-23-003058 · form4-02232023_120257.xml · nonDerivative · entry 1 Morrone Louis H. · CIK 0001867666 · SENIOR VICE PRESIDENT 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 57,282 F1 · shares: These shares represent a performance-based restricted stock award under the Abbott Laboratories 2017 Incentive Stock Program. The award has a 3-year term, with no more than 1/3 of the award vesting in any one year upon Abbott reaching a minimum return on equity target. The award includes the right to have shares withheld for tax purposes. Read SEC document |
| July 01, 2022 Filed Jul 1, 2022 20:34 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | Tax withholdingCommon shares without par value | 556 | $108.65 | $60,409.40 |
DisclosureSEC source: 0001415889-22-007182 · form4-07012022_010722.xml · nonDerivative · entry 1 Morrone Louis H. · CIK 0001867666 · SENIOR VICE PRESIDENT 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 46,722 Read SEC document |
| March 01, 2022 Filed Mar 3, 2022 00:54 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | SaleCommon shares without par value | 656 | $118.16 | $77,513.16 |
DisclosureSEC source: 0001415889-22-002198 · form4-03022022_040330.xml · nonDerivative · entry 2 Morrone Louis H. · CIK 0001867666 · SENIOR VICE PRESIDENT 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 47,278 Read SEC document |
| March 01, 2022 Filed Mar 3, 2023 00:47 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | SaleCommon shares without par value | 1,092 | $100.70 | $109,964.40 |
DisclosureSEC source: 0001415889-23-003913 · form4-03032023_120307.xml · nonDerivative · entry 2 Morrone Louis H. · CIK 0001867666 · SENIOR VICE PRESIDENT 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 53,656 Read SEC document |
| February 28, 2022 Filed Mar 3, 2022 00:54 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | Tax withholdingCommon shares without par value | 1,942 | $122.41 | $237,720.22 |
DisclosureSEC source: 0001415889-22-002198 · form4-03022022_040330.xml · nonDerivative · entry 1 Morrone Louis H. · CIK 0001867666 · SENIOR VICE PRESIDENT 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 47,934 Read SEC document |
| February 18, 2022 Filed Feb 24, 2022 01:26 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | GrantOption (right to buy) · Derivative | 54,280 | $0.00 Strike: $117.58 | $0.00 |
DisclosureSEC source: 0001415889-22-001743 · form4-02232022_050216.xml · derivative · entry 3 Morrone Louis H. · CIK 0001867666 · SENIOR VICE PRESIDENT 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 54,280 Underlying: Common Shares · 54,280 shares Expires 2032-02-17 F3 · security: Employee stock option granted pursuant to the Abbott Laboratories 2017 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3. The option becomes exercisable in annual increments of 18,093 on February 18, 2023, 18,093 on February 18, 2024, and 18,094 on February 18, 2025. Read SEC document |
| February 18, 2022 Filed Feb 24, 2022 01:26 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | GrantCommon shares without par value | 11,647 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-22-001743 · form4-02232022_050216.xml · nonDerivative · entry 1 Morrone Louis H. · CIK 0001867666 · SENIOR VICE PRESIDENT 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 49,876 F1 · shares: These shares represent a performance-based restricted stock award under the Abbott Laboratories 2017 Incentive Stock Program. The award has a 3-year term, with no more than 1/3 of the award vesting in any one year upon Abbott reaching a minimum return on equity target. The award includes the right to have shares withheld for tax purposes. Read SEC document |
| December 17, 2021 Filed Dec 21, 2021 22:38 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | Exercise / conversionOption (right to buy) · Derivative | 9,988 | $0.00 Strike: $48.34 | $0.00 |
DisclosureSEC source: 0001415889-21-006162 · form4-12212021_021252.xml · derivative · entry 4 Morrone Louis H. · CIK 0001867666 · SENIOR VICE PRESIDENT 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Shares · 9,988 shares Expires 2027-07-09 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · security: Employee stock option granted pursuant to the Abbott Laboratories 2017 Incentive Stock Program, in a transaction exempt from Section 16 under Rule 16b-3. Read SEC document |
| December 17, 2021 Filed Dec 21, 2021 22:38 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | SaleCommon shares without par value | 9,988 | $137.54 | $1,373,749.52 |
DisclosureSEC source: 0001415889-21-006162 · form4-12212021_021252.xml · nonDerivative · entry 2 Morrone Louis H. · CIK 0001867666 · SENIOR VICE PRESIDENT 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 38,229 Read SEC document |
| December 17, 2021 Filed Dec 21, 2021 22:38 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | Exercise / conversionCommon shares without par value | 9,988 | $48.34 | $482,819.92 |
DisclosureSEC source: 0001415889-21-006162 · form4-12212021_021252.xml · nonDerivative · entry 1 Morrone Louis H. · CIK 0001867666 · SENIOR VICE PRESIDENT 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 48,217 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| December 07, 2021 Filed Dec 8, 2021 22:25 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | Exercise / conversionOption (right to buy) · Derivative | 9,988 | $0.00 Strike: $48.34 | $0.00 |
DisclosureSEC source: 0001415889-21-005787 · form4-12082021_021237.xml · derivative · entry 7 Morrone Louis H. · CIK 0001867666 · SENIOR VICE PRESIDENT 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,988 Underlying: Common Shares · 9,988 shares Expires 2027-07-09 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · security: Employee stock option granted pursuant to the Abbott Laboratories 2017 Incentive Stock Program, in a transaction exempt from Section 16 under Rule 16b-3. Read SEC document |
| December 07, 2021 Filed Dec 8, 2021 22:25 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | SaleCommon shares without par value | 9,988 | $134.00 | $1,338,392.00 |
DisclosureSEC source: 0001415889-21-005787 · form4-12082021_021237.xml · nonDerivative · entry 4 Morrone Louis H. · CIK 0001867666 · SENIOR VICE PRESIDENT 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 38,229 Read SEC document |
| December 07, 2021 Filed Dec 8, 2021 22:25 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | Exercise / conversionCommon shares without par value | 9,988 | $48.34 | $482,819.92 |
DisclosureSEC source: 0001415889-21-005787 · form4-12082021_021237.xml · nonDerivative · entry 3 Morrone Louis H. · CIK 0001867666 · SENIOR VICE PRESIDENT 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 48,217 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| December 06, 2021 Filed Dec 8, 2021 22:25 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | Exercise / conversionOption (right to buy) · Derivative | 9,989 | $0.00 Strike: $48.34 | $0.00 |
DisclosureSEC source: 0001415889-21-005787 · form4-12082021_021237.xml · derivative · entry 6 Morrone Louis H. · CIK 0001867666 · SENIOR VICE PRESIDENT 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 19,976 Underlying: Common Shares · 9,989 shares Expires 2027-07-09 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · security: Employee stock option granted pursuant to the Abbott Laboratories 2017 Incentive Stock Program, in a transaction exempt from Section 16 under Rule 16b-3. Read SEC document |
| December 06, 2021 Filed Dec 8, 2021 22:25 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | SaleCommon shares without par value | 9,989 | $131.01 | $1,308,683.86 |
DisclosureSEC source: 0001415889-21-005787 · form4-12082021_021237.xml · nonDerivative · entry 2 Morrone Louis H. · CIK 0001867666 · SENIOR VICE PRESIDENT 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 38,229 F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $131.00 to $131.16, inclusive. The reporting person undertakes to provide to Abbott Laboratories, any security holder of Abbott Laboratories, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. Read SEC document |
| December 06, 2021 Filed Dec 8, 2021 22:25 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | Exercise / conversionCommon shares without par value | 9,989 | $48.34 | $482,868.26 |
DisclosureSEC source: 0001415889-21-005787 · form4-12082021_021237.xml · nonDerivative · entry 1 Morrone Louis H. · CIK 0001867666 · SENIOR VICE PRESIDENT 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 48,218 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| July 01, 2021 Filed Jul 6, 2021 21:22 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | GrantOption (right to buy) · Derivative | 19,291 | $0.00 Strike: $116.40 | $0.00 |
DisclosureSEC source: 0001415889-21-003513 · form4-07062021_020716.xml · derivative · entry 3 Morrone Louis H. · CIK 0001867666 · SENIOR VICE PRESIDENT 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 19,291 Underlying: Common Shares · 19,291 shares Expires 2031-06-30 F3 · security: Employee stock option granted pursuant to the Abbott Laboratories 2017 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3. The option becomes exercisable in annual increments of 6,430 on July 1, 2022, 6,430 on July 1, 2023, and 6,431 on July 1, 2024. Read SEC document |
| July 01, 2021 Filed Jul 6, 2021 21:22 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | GrantCommon shares without par value | 3,764 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-21-003513 · form4-07062021_020716.xml · nonDerivative · entry 1 Morrone Louis H. · CIK 0001867666 · SENIOR VICE PRESIDENT 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 38,229 F1 · shares: These shares represent a performance-based restricted stock award under the Abbott Laboratories 2017 Incentive Stock Program. The award has a 3-year term, with no more than 1/3 of the award vesting in any one year upon Abbott reaching a minimum return on equity target. The award includes the right to have shares withheld for tax purposes. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.